How To Validate A Novel Primary Endpoint: Ampyra's Lineup Of Pivotal Trial Endpoints & Analyses
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Acorda conducted two fundamentally identical Phase III trials for Ampyra (dalfampridine), studies MS-F203 and MS-F204. The trials, with a novel primary endpoint for the multiple sclerosis setting, were conducted under Special Protocol Assessments from FDA. Since the primary endpoint was untested and for an unprecedented indication (and involved a complex analysis plan), the secondary endpoints were of particular importance in providing reassurance of the drug's effect.